ClinicaliQ Trial Snapshot
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) — Active Not Recruiting • Phase III • Oncology • NCT04784715.
- New antibody-drug conjugate T-DXd, with or without pertuzumab, compared to standard chemotherapy for HER2-positive advanced breast cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting. Conditions: Breast Cancer; HER2-positive; Metastatic Interventions: Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab Lead Sponsor: AstraZeneca Planned Enrollment: 1157 participants